Stock screener

DNLI

Conviction 46HealthcareScan · Thu, Sep 24, 2026

Denali Therapeutics Inc. (DNLI) closed at $20.48 (+0.10%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 38, RS Rating 83, -24.7% from its 52-week high, +25.9% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

DNLI$20.48+0.10%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 1.8M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Denali Therapeutics Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.denalitherapeutics.com ↗
Price20.48
Change+0.10%
Gap-0.71%
Rel volume1.76×
Avg volume1.63M
Avg $ vol34.87M
SMA 2021.71
SMA 5023.19
SMA 20020.99
Price vs 50-11.68%
Price vs 200-2.42%
MA stackmixed
50/200 cross—
Supertrenddown · 22.13
RSI (14)38
MACD hist-0.03
MACD cross—
Stoch %K / %D35 / 38
ADX (14)32
+DI / −DI18 / 29
RSI divergence—
MACD divergenceBearish
ATR %4.35%
ADR %3.58%
52w high27.21
52w low13.43
From 52w high-24.73%
Above 52w low+52.49%
New 52w highNo
SqueezeOff
Bollinger width26.02%
%B0.28
Donchian pos20.22%
Donchian high24.74
Donchian low19.40
AVWAP (52w high)23.12
vs AVWAP high-11.43%
AVWAP (52w low)20.04
vs AVWAP low+2.20%
OBV trendDown
Chaikin MF (20)-0.07
Today vs 20d1.76×
Avg vol (14d)1.8M
Avg vol (20d)1.63M
Avg $ vol (20d)34.87M
Market cap3.27B
RS Rating83 / 99
RS 3m (vs SPY)-21.68%
RS 6m (vs SPY)-25.67%
RS line new highNo
Trend template5/8
Technical rank37.6
1 week+1.74%
1 month-17.85%
3 months-17.19%
6 months-8.86%
1 year+56.93%
YTD+25.88%
P/E-6.39
P/B3.92
P/S—
P/FCF-7.76
EPS-2.97
Div yield—
ROE-61.37%
ROA-44.26%
Debt/Eq—
Current8.37
EV/EBITDA-5.65
Gross margin—
Net margin—
Rev growth—
EPS growth-21.23%
Price target35.92
Target upside75.39%
Analyst ratingBuy
Institutional106.59%
Ent. value3.07B
Revenue3.6M
Net income-127.55M
Gross profit—
Free cash flow-422.1M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out158.71M
Employees507
ListedFri, Dec 8, 2017
Free float128.21M
Float %87.4%
Short interest16.64M
Days to cover17.5d
Short volume55.1%
Squeeze score72 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.68 vs −$0.72
Last surprise+5.6% beat
Setup gradeC
Conviction46 / 100
Pattern quality—
Tech rank37.6 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance25.69
Support21.01
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Recent news

Congress activity

Disclosed STOCK Act trades in DNLI

All disclosures →
No recent disclosed trades by Congress in DNLI. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in DNLI · open-market 2 sells

InsiderSideShares
Chin Peter Scott
Chief Medical Officer · Common Stock · 2026-09-04
Sell1.65K
Watts Ryan J.
President and CEO · Common Stock · 2026-08-12
Gift32.22K
Schuth Alexander O.
COFO and Secretary · Common Stock · 2026-08-11
Sell2.86K
Baker Brothers Life Sciences LP
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER JULIAN
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER FELIX
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER JULIAN
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
Baker Bros. Advisors (GP) LLC
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
BAKER BROS. ADVISORS LP
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
BAKER BROS. ADVISORS LP
Director · Non-Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K

SEC filings

EDGAR filings in DNLI · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.